A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib

Phase 1

Terminated

• Conditions: Solid Tumor
• Interventions: Drug: 14C-labeled poziotinib

• Registration Number: NCT03804515
• Lead Sponsor: Spectrum Pharmaceuticals, Inc

Brief Summary

The purpose of this study is to determine routes of excretion and single-dose PK parameters for poziotinib in patients with solid tumors with EGFR or HER2 mutations or EGFR/HER2 overexpression/amplification.

Detailed Description

This is a Phase 1, open-label, single-dose study of 14C-labeled poziotinib to determine routes of excretion and single-dose PK parameters for poziotinib in patients with solid tumors with EGFR or HER2 mutations or EGFR/HER2 overexpression/amplification.

On Day 1, enrolled patients will be admitted to the inpatient unit and all predose assessments will be completed. Patients will be admitted to the inpatient unit for 9 days. On Day 2, a single capsule containing 12 mg of 14C-labeled poziotinib (approximately 90 to 110 μCi) will be administered orally in the morning right after breakfast with at least 200 mL of water.

Over the following 168 hours, urine and feces will be collected and pooled at specified intervals for measurement of total radioactivity recovered and subsequent determination of the routes of elimination of poziotinib and its metabolites. Blood samples will be taken at specified time points for 168 hours after dosing for estimation of single-dose poziotinib PK parameters.

Study Timeline

• Study First Submitted: 2019-01-11
• Study First Submitted QC: 2019-01-11
• Study First Posted: 2019-01-15
• Study Start: 2019-06-25
• Primary Completion: 2020-02-20
• Study Completion: 2020-06-17
• Status Verified: 2021-06
• Last Update Submitted: 2021-06-14
• Last Update Posted: 2021-06-15

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 2

Inclusion Criteria

• Patient can be male or female and is at least 18 years of age
• Patient must be willing and capable of giving written Informed Consent and willing to stay in the research unit for 9 days.
• Patient has a life expectancy of at least 6 months.
• Histological confirmation of solid tumor cancer that is suitable for poziotinib therapy. These may include patients with any solid malignancy with either EGFR or HER 2 mutations or EGFR/HER2 overexpression/amplification. Brain metastases are allowed, if patient is clinically stable and does not require treatment with anticonvulsants or escalating steroid doses.

Exclusion Criteria

• Patient has a diagnosis of primary and or metastatic hepatic or renal carcinomas.
• Patient is unable to take oral medication or has ongoing Grade ≥2 diarrhea due to any etiology including Crohn's disease and/or ulcerative colitis.
• Previous poziotinib exposure
• Patient has previously participated in a study utilizing 14C.
• Patient has any pathology or history of procedures expected to change absorption
• Patient has a PEG (Percutaneous Endoscopic Gastrostomy) tube

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
14C-labeled Poziotinib	14C-labeled poziotinib	-

Primary Outcome Measures

Name	Time	Method
Maximum recovery of the radioactive dose in plasma, urine and feces	1 year	The route of excretion of radioactive poziotinib and its metabolites following single oral administration of 14C-labeled poziotinib in patients with solid tumors suitable for treatment with poziotinib.

Secondary Outcome Measures

Name	Time	Method
The concentration of 14C-labeled poziotinib and its metabolites in plasma, urine and feces	1 year	To identify major metabolites of poziotinib

Trial Locations

Locations (1)

UPMC Hillman Cancer Center; 🇺🇸 Pittsburgh, Pennsylvania, United States